Core Insights - Evercore reported a revenue of $980.5 million for the quarter ended December 2024, marking a 25% increase year-over-year and a surprise of +12.81% over the Zacks Consensus Estimate of $869.15 million [1] - The earnings per share (EPS) for the quarter was $3.41, compared to $2.02 in the same quarter last year, resulting in an EPS surprise of +17.59% against the consensus estimate of $2.90 [1] Financial Performance Metrics - Net Revenues from Other Revenue were reported at $24.42 million, exceeding the average estimate of $22.50 million, but reflecting a -23.2% change year-over-year [4] - Adjusted Net Revenues from Investment Management, specifically Asset Management and Administration Fees, were $22.04 million, slightly below the average estimate of $22.22 million, showing a +16.3% year-over-year change [4] - Adjusted Net Revenues from Investment Banking & Equities totaled $958.20 million, significantly surpassing the average estimate of $823.93 million, with a year-over-year increase of +24.3% [4] Stock Performance - Over the past month, Evercore's shares have returned +2.9%, outperforming the Zacks S&P 500 composite's +1.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Evercore (EVR) reported quarterly earnings of $3.41 per share, exceeding the Zacks Consensus Estimate of $2.90 per share, and showing a significant increase from $2.02 per share a year ago, representing an earnings surprise of 17.59% [1] - The company achieved revenues of $980.5 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 12.81% and up from $784.17 million year-over-year [2] - Evercore has outperformed consensus EPS estimates three times in the last four quarters and has also topped revenue estimates three times during the same period [2] Earnings Outlook - The sustainability of Evercore's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $3.70, with expected revenues of $808.09 million, and for the current fiscal year, the EPS estimate is $16.08 on revenues of $3.76 billion [7] Industry Context - The Financial - Investment Bank industry, to which Evercore belongs, is currently ranked in the top 1% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Fourth Quarter Net Revenues were $975.3 million, a 24% increase year-over-year, and Full Year Net Revenues reached $3.0 billion, up 23% from 2023[1] - Fourth Quarter Operating Income was $212.6 million, an 81% increase year-over-year, with Operating Margins of 21.8%, up 679 basis points from 2023[1] - Net Income Attributable to Evercore Inc. for Q4 was $140.4 million, a 70% increase year-over-year, and Full Year Net Income was $378.3 million, up 48% from 2023[1] - Total revenues for the twelve months ended December 31, 2024, were $2,996.4 million, up from $2,442.7 million in 2023, representing a 22.7% increase[54] - Net income attributable to Evercore Inc. for the twelve months ended December 31, 2024, was $378.3 million, compared to $255.5 million in 2023, reflecting a 48.1% increase[54] - Basic net income per share attributable to Evercore Inc. common shareholders increased to $9.86 in 2024 from $6.71 in 2023[54] - Adjusted Net Revenues for Q4 2024 were $790.3 million, a 24% increase from Q4 2023, while full year adjusted net revenues reached $3.0 billion, up 23% year-over-year[25] - Adjusted Net Revenues for the twelve months ended December 31, 2024, were $3.0 billion, up 22.5% from $2.4 billion in 2023[59] - Adjusted Operating Income for Q4 2024 was $217.7 million, representing an increase of 75.8% compared to $123.9 million in Q4 2023[59] - Diluted Earnings Per Share (EPS) for Q4 2024 was $3.30, up 62.1% from $2.03 in Q4 2023[59] - Adjusted Diluted EPS for the twelve months ended December 31, 2024, was $9.42, a 46.5% increase from $6.46 in 2023[59] Advisory and Underwriting Fees - Advisory Fees for Q4 increased by $190.2 million, or 29%, year-over-year, while Full Year Advisory Fees rose by $476.7 million, or 24%[14] - Underwriting Fees for Q4 increased by $7.3 million, or 38%, year-over-year, with Full Year Underwriting Fees up by $46.1 million, or 41%[15] - Advisory fees in Q4 2024 increased by $190.0 million, or 29%, year-over-year, driven by large transactions[27] - Underwriting Fees for Q4 2024 rose by $7.3 million, or 38%, year-over-year, reflecting an increase in transaction participation[28] - Advisory fees increased to $849.556 million in Q4 2024, up 28.9% from $659.338 million in Q4 2023[67] Assets and Shareholder Returns - Total Assets Under Management as of December 31, 2024, were $13.9 billion, reflecting a 13% increase from $12.3 billion in 2023[13] - Evercore returned $590.6 million to shareholders in 2024 through dividends and share repurchases[1] - As of December 31, 2024, cash and cash equivalents were $873.0 million, with current assets exceeding current liabilities by $1.8 billion[36] - The Company declared a quarterly dividend of $0.80 per share to be paid on March 14, 2025[43] - In Q4 2024, the Company repurchased 14,000 shares at an average price of $297.41 and 0.1 million shares at an average price of $269.06, totaling 2.3 million shares repurchased throughout 2024 at an average price of $193.40[44] Employee Compensation and Costs - Employee Compensation and Benefits increased by $79.5 million, or 14%, year-over-year in Q4 2024, with a compensation ratio of 65.6% compared to 71.4% in Q4 2023[19] - Full year Employee Compensation and Benefits increased by $317.2 million, or 19%, year-over-year, with a full year compensation ratio of 66.3% versus 68.3% in the prior year[19] - Non-Compensation Costs rose by $16.8 million, or 16%, year-over-year in Q4 2024, primarily due to increased professional fees and occupancy expenses[20] - Full year adjusted Non-Compensation Costs increased by $64.3 million, or 16%, year-over-year, with a full year adjusted Non-Compensation ratio of 15.8% down from 16.8%[20] - Employee compensation and benefits for the full year 2024 totaled $1.974036 billion, up 19.1% from $1.656875 billion in 2023[67] Future Outlook - The company expects strong momentum to continue into 2025, with gradual market improvement anticipated throughout the year[3] - Future guidance indicates a projected revenue growth of 5-7% for the upcoming fiscal year, driven by increased advisory activity and market expansion[64] - The company plans to expand its market presence through strategic acquisitions and new product offerings in 2025[64] Segment Performance - Investment Banking & Equities segment net revenues for Q4 2024 reached $958.2 million, a 3.5% increase from Q4 2023's $770.7 million[64] - Total expenses for the Investment Banking & Equities segment in Q4 2024 were $745.9 million, compared to $653.9 million in Q4 2023, reflecting a 14.1% increase[64] - Operating income for the Investment Banking & Equities segment in Q4 2024 was $212.3 million, a 12.5% increase from $116.7 million in Q4 2023[64] - Investment Management segment net revenues for Q4 2024 were $22.3 million, up from $19.7 million in Q4 2023, indicating a 7.5% increase[64] - Operating income for the Investment Management segment in Q4 2024 was $5.4 million, compared to $7.1 million in Q4 2023, showing a decrease of 24.0%[64]

Investment Strategy - The Value Lab focuses on long-only value ideas, targeting international mispriced equities with a portfolio yield of about 4% [1] - The Valkyrie Trading Society shares high-conviction developed market ideas that are downside limited and aim to generate non-correlated and outsized returns [3] Services Offered - The Value Lab provides members with a portfolio featuring real-time updates, 24/7 chat support, global market news reports, feedback on member stock ideas, new trades monthly, quarterly earnings write-ups, and daily macro opinions [2] Performance and Experience - The Value Lab has performed well over the last 5 years, leveraging experience in international markets [1]

SECAUCUS, N.J., Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami on Wednesday, December 4, 2024, at 3:00 p.m. Eastern Time.The fireside chat and Q&A session will be webcast live during the conference and will be ...

CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 7th Annual Evercore ISI HealthCONx Conference. Management is scheduled to participate in a fireside chat discussion on December 5, 2024, at 8:20 am ET. Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at htt ...

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference  Presentation Date:December 4, 2024  Time:7:55 ...

Core Insights - Mapi Pharma Ltd. is participating in the 7th Annual Evercore HealthCONx Conference from December 3-5, 2024, in Coral Gables, Florida, to explore partnership opportunities for its innovative long-acting depot injectable treatments [1][2]. Company Overview - Mapi Pharma is a fully integrated, late-stage clinical development biopharmaceutical company focused on developing Lifecycle Management products using extended-release Depot technologies across various therapeutic areas, including multiple sclerosis (MS), diabetes, and schizophrenia [3][6]. - The company has a strong intellectual property (IP) portfolio and is engaged in the development of high barrier-to-entry and high added-value life cycle management products [6]. Development and Manufacturing Capabilities - Mapi Pharma has a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply, allowing for efficient integration of R&D, clinical studies, registration, and manufacturing [4]. - The company has a dedicated R&D team and Depot labs, which enhance its capabilities in developing Depot products [4]. Partnership Opportunities - Mapi Pharma is actively seeking partnerships for its proprietary Depot products, including Deutetrabenazine (AUSTEDO® XR) Depot for Huntington's disease and Anastrazole (Arimidex®) Depot for hormone receptor-positive early breast cancer [5]. - The company offers to conduct formulation development, preclinical studies, and manage clinical development for partners, who will finance development costs and handle commercialization [5]. Product Pipeline - Mapi's lead product, GA Depot, is partnered with Viatris for the treatment of Relapsing Forms of Multiple Sclerosis (RMS) and is currently under FDA review following successful Phase 3 results [6]. - The company is also developing Depot drugs for various conditions, including schizophrenia, diabetes, weight control, Parkinson's disease, and potentially Alzheimer's [6].

Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's disease, Parkinson's disease, schizophrenia, and other CNS diseases [3] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3] - ANAVEX®2-73 targets SIGMAR1 and muscarinic receptors, aiming to restore cellular homeostasis and has demonstrated various beneficial properties in preclinical studies [3] Upcoming Events - Christopher U. Missling, PhD, President and CEO of Anavex, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024 [1] - The conference will feature over 600 industry experts and corporate leaders from more than 225 healthcare companies, covering major healthcare verticals [2] Research and Development - Anavex has received a research grant from The Michael J. Fox Foundation for Parkinson's Research to support the development of ANAVEX®2-73 for Parkinson's disease [3] - Another drug candidate, ANAVEX®3-71, is in clinical stages and shows promise in addressing Alzheimer's disease hallmarks in preclinical trials [3]

NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media ...